Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate enGene Therapeutics Inc. before investing.

In this article, we go over a few key elements for understanding enGene Therapeutics Inc.’s stock price such as:

• enGene Therapeutics Inc.’s current stock price and volume
• Why enGene Therapeutics Inc.’s stock price changed recently
• Upgrades and downgrades for ENGN from analysts
• ENGN’s stock price momentum as measured by its relative strength

About enGene Therapeutics Inc. (ENGN)

Before we jump into enGene Therapeutics Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

enGene Therapeutics Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company in Canada. The company develops genetic medicines to help patients suffering from bladder cancer. Its lead product candidate is detalimogene voraplasmid, a monotherapy for the treatment of non-muscle invasive bladder cancer (NMIBC). Its pipeline includes LEGEND, which is in Phase 2. The company was formerly known as enGene Holdings Inc. and changed its name to enGene Therapeutics Inc. in April 2026. enGene Therapeutics Inc. is based in Montreal, Canada.

Want to learn more about enGene Therapeutics Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about enGene Therapeutics Inc..

enGene Therapeutics Inc.’s Stock Price as of Market Close

As of September 11, 2026, 3:10 PM, CST, enGene Therapeutics Inc.’s stock price was $1.805.

enGene Therapeutics Inc. is up 1.98% from its previous closing price of $1.770.

During the last market session, enGene Therapeutics Inc.’s stock traded between $1.790 and $1.830. Currently, there are approximately 69.73 million shares outstanding for enGene Therapeutics Inc..

enGene Therapeutics Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

enGene Therapeutics Inc. Stock Price History

enGene Therapeutics Inc.’s (ENGN) price is currently down 1.9% so far this month.

During the month of September, enGene Therapeutics Inc.’s stock price has reached a high of $1.940 and a low of $1.760.

Over the last year, enGene Therapeutics Inc. has hit prices as high as $12.250 and as low as $1.400. Year to date, enGene Therapeutics Inc.’s stock is down 80.01%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused enGene Therapeutics Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 10, 2026, there was 1 analyst who downgraded enGene Therapeutics Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate enGene Therapeutics Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on enGene Therapeutics Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

enGene Therapeutics Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about enGene Therapeutics Inc. (ENGN) by visiting AAII Stock Evaluator.

Relative Price Strength of enGene Therapeutics Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 10, 2026, enGene Therapeutics Inc. has a weighted four-quarter relative price strength of -10.70%, which translates to a Momentum Score of 23 and is considered to be Weak.

Want to learn more about how enGene Therapeutics Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

enGene Therapeutics Inc. Stock Price: Bottom Line

As of September 11, 2026, enGene Therapeutics Inc.’s stock price is $1.805, which is up 1.98% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like enGene Therapeutics Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.